|
| |
Geneva Pharmaceuticals
Geneva Pharmaceuticals belongs to |
| shareholder | country % source |
|
|
name  items photo compare the prices |
Shop local, ethical and at the best price on Ethishop ! |
|
|
« ETHICAL » RATING OF GENEVA_PHARMACEUTICALS
, group
Novartis AG
and subsidiaries
[click on the images below or on help for more information] |
| Human: 1 violation(s) of fundamental human rights |
| Job: 6% of company's jobs cut since 1998 |
| Environment: 9 major pollution(s) |
| Delinquency: 3 act(s) of financial or trade delinquency |
| Tax haven, secret bank account, shell companies: operates in 13 offshore financial center(s) |
| Sales: more than 37 billion(s) dollars/euros in annual sales |
| Net profit: more than 44 billion(s) dollars/euros in cumulated net profit since 1998 |
| Top management: earns 637 times the median income in the United States (32000 US$/year) |
| Influence: 13 act(s) of direct corruption or lobbying |
| Advertising & marketing: 4 dubious practice(s) |
|
| |
|
year | financial misdemeanor | | | | | source |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. |
| | | | | | Canadian P.  |
|
|
|
|
Also announce a documentary, a book or an article or comment this company profile.
Goal: present the company activities, improve the ethical rating's accuracy, develop an network of observers.